German researchers find reason for remdesi...German Researchers have unraveled how remdesivir interferes with the viral RNA polymerase and why it does not block SARS-CoV-2 completely. more ➔
LSP reports first closing of dementia fundEuropean life sciences investors LSP has closed a new fund to fight dementia at €50m. more ➔
Valneva in talks with EU about 60 million...French Valneva SE announced it is in advanced discussions with the European Commission (EC) for the supply of up to 60 million doses of its COVID-19 vaccine, VLA2001. more ➔
Immunocore bags US$75m in Series C roundImmuno-oncology specialist Immunocore plc announced the completion of a $75m Series C private financing round. more ➔
EU approves second COVID-19 vaccineFollowing a recommendation by the European Medicines Agency (EMA), the European Commission has approved a second vaccine against the novel coronavirus SARS-CoV-2. more ➔
Angelini Pharma to take over Arvelle Thera...Italian Angelini Pharma and Swiss CNS disease specialist Arvelle Therapeutics have entered into a definitive merger agreement. more ➔
COVID-19 test gives results within minutesUniversity of Birmingham researchers have invented a COVID-19 RNA test that reduces testing time from 30 minutes to under five, and delivers accurate results. more ➔
Merry Christmas and a Happy New YearDear readers,We wish all visitors to our news page a peaceful and healthy New Year and a successful start to the New Year. Stay healthy! We will be back with the latest news from 4 January.Best … more ➔
EMA greenlights BioNtech’s COVID-19...Following a rapid FDA approval, the European drug authority EMA has recommended to conditionally approve BioNTechs mRNA vaccine BNT162b2 in the EU. more ➔
European Circular Bioeconomy Fund growingOnly two and a half months after its launch, the EU bioecocomy venture capital fund ECBF has doubled the volume of its first closing. more ➔